Treats metastatic non-small cell lung cancer (NSCLC). Sold as Tabrecta. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Capmatinib Hydrochloride (sold as Tabrecta), first approved May 6, 2020, with 1 new use approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Tabrecta | Part D | $165M | +33% | 1,531 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided TherayLung Cancer, Gene Abnormality · Second Affiliated Hospital of Guangzhou Medical University | — | Recruiting | Jun 20, 2017 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| May 6, 2020 | TabrectaNDA 213591 · New molecular entity | Novartis Pharm | 4 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA